Video Center

The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, tells us how vaccines can be used to broaden the use of immunotherapies in GI cancer patients

Published: 24 January 2017

Recent Videos: ASCO GI Conference Coverage

video

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the quality of life data from the NETTER-1 study

video

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the results of the NETTER-1 study

video

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...

video

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on whether resected pancreatic cancer patients should be offered adjuvant ...

video

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on which molecular tests to order for a newly diagnosed ...

video

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how checkpoint inhibitors are being integrated into treatment of ...

video

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how to integrate genetic mutations, and left sided vs ...

video

John L. Marshall, MD, talks about the results of the RESORCE trial

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, talks about the results of the RESORCE trial and how ...

video

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, shares his perspective on how to use both TAS-102 and ...

video

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, talks about some considerations when treating a newly diagnosed stage ...

video

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, tells us how vaccines can be used to broaden the ...

video

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how checkpoint inhibitors will be incorporated into the treatment of unresectable HCC

video

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on if the RESORCE trial will change ...

video

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on whether physicians will incorporate regorafenib into clinical practice

video

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how new agents being studied for advanced HCC will be integrated into ...

video

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on identifying subgroups of HCC patients that ...

video

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses which molecular tests to order for ...

video

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...

video

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on integrating immunotherapy into existing treatment regimens for CRC patients

video

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on reliably identifying subgroups of patients for targeted therapies in HCC

video

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, explains how the 80405 study in CRC ...

video

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, provides his perspective on how to use ...

video

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, discusses which molecular tests to order when determining treatment approach ...

video

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, talks about the DFCI wellness study demonstrating that CRC patients ...

video

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...

video

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, discusses the outcomes of the RESORCE trial as presented here at ASCO GI ...

video

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

Dr. Hochster, Associate Director, Yale Cancer Center, differentiates regorafenib from 5FU and TAS-102 from a mechanism of action perspective

video

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

Dr. Hochster, Associate Director, Yale Cancer Center, explains the outcomes of the randomized phase 2 study in BRAF mutated CRC ...

video

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

Dr. Hochster, Associate Director, Yale Cancer Center, on integrating immunotherapy into existing treatment regimens for GI cancer patients

video

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

Dr. Hochster, Associate Director, Yale Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a ...

video

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

Dr. Hochster, Associate Director, Yale Cancer Center, discusses if genetic profiling has changed the approach to treating CRC patients

video

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses how checkpoint inhibitors be incorporated into the treatment of unresectable HCC

video

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses the outcomes of the RESORCE trial

video

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, shares his thoughts on whether physicians will incorporate regorafenib into clinical practice

video

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, on identifying subgroups of patients for targeted therapies in HCC

video

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, explains how new agents in advanced HCC are being integrated into treatment

video

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how organoids are being used for cancer biology research

video

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, talks about how integrating immunotherapy into existing treatment regimens for CRC ...

video

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how the Blue Ribbon Panel may help with the Cancer ...

video

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, discusses the goals of the NCI-MATCH trial and the progress to ...

video

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted ...

video

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains how checkpoint inhibitors will be incorporated ...

video

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, shares her thoughts on whether physicians will ...

video

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses how new agents being studied for ...

video

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains the outcomes of the RESORCE trial ...

video

Johanna Bendell, MD, discusses the RESORCE trial data

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, provides her expectations on how the RESORCE trial data ...

video

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the Proprietary Neoantigen Identification Technology platform

video

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses integrating immunotherapy into existing treatment regimens for GI cancer ...

video

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains which molecular tests help determine treatment approach

video

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the outcomes of the randomized phase 2 study in ...

video

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the phase 3 study in advanced gastric ...

video

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, shares her thoughts on some exciting trials or drugs ...

video

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, discusses some of the challenges in treating pancreatic cancer

video

STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm ...

video

Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses regorafenib experience and integrating TAS-102 for advanced CRC at ASCO GI 2016.

video

Planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers ASCO Gi 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses planned studies to evaluate immune checkpoint inhibitors in MMR ...

video

How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses how has the last 10 years changed the way you treat metastatic colorectal ...

video

Potential cases to use Regorafenib over TAS-102 ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses potential cases to use Regorafenib over TAS-102 ASCO GI 2016.

video

More money should be allocated to early detection and screening in colorectal cancer ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses why more money should be allocated to early detection and screening in colorectal ...

video

Biggest questions facing the treatment of colorectal cancer ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the biggest questions facing the treatment of colorectal cancer at ASCO GI 2016.

video

PD-L1 markers in MMR deficient cancers ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses PD-L1 markers in MMR deficient cancers at ASCO GI ...

video

Mismatch Repair (MMR) deficient and the use of PD-1 blockade ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses Mismatch Repair (MMR) deficient and the use of PD-1 ...

video

ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how ERCC1 not a valid prognostic or predictive factor ...

video

RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses RAS mutation in patients with metastatic colorectal cancer at ...

video

Design of the RECOURSE trial on which the FDA approved TAS-102

Axel Grothey, MD of Mayo Clinic discusses the design of the RECOURSE trial on which the FDA approved TAS-102 at ...

video

RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC

Axel Grothey, MD of Mayo Clinic discusses the RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC at ...

video

Importance of performance status prior to starting regorafenib at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses the importance of performance status prior to starting regorafenib ...

video

Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ...

video

Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses which EGFR inhibitor to use in second line treatment ...

video

TAS-102 versus 5-flourouracil and other more familiar agents ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses TAS-102 versus 5-flourouracil and other more familiar agents at ...

video

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in ...

video

RECOURSE trial did performance status impact benefit from TAS-102 at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses RECOURSE trial and if performance status impact benefit from ...

video

Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses integrating TAS-102 and regorafenib into your therapeutic algorithm for ...

video

ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer

Al B. Benson, MD of Northwestern University discusses the optimal dosage using Regorafenib in colorectal cancer at ASCO GI 2016. ...

video

Managing patients on regorafenib including adverse events

Al B Benson, MD of Northwestern University discusses managing patients on regorafenib including adverse events at ASCO GI 2016.

video

Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies

Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses the next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials ...

video

KEYNOTE-028 results with pembrolizumab

Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses KEYNOTE-028 results with pembrolizumab at ASCO GI 2016.

video

Pembrolizumab looks promising according to KEYNOTE-028 results

Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab looks promising according to KEYNOTE-028 results at ...

video

Immunotherapy Shows Promise in MSI-High Colorectal Cancer

Davendra Sohal, MD of Cleveland Clinic discusses promise in MSI-High Colorectal Cancer at ASCO GI 2016.

video

Pancreatic Cancer News from ASCO GI 2016

Davendra Sohal, MD of Cleveland Clinic discusses Pancreatic Cancer News from ASCO GI 2016.

video

Weekly T-DM1 surprising or disappointing ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses weekly T-DM1 surprising or disappointing at ASCO GI 2016.

video

GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses GATSBY trial results T-DM1 in previously treated gastric and GE ...

video

Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at ...

video

Post-operative adjuvant therapy for resectable patients with node positive oesophageal cancer ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses post-operative adjuvant therapy for resectable patients with node positive esophageal ...

video

FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or ...

video

Future of TAS-102 and regorafenib for patients with colorectal cancer

Howard S Hochster, MD of Yale Medical Center discusses the future of TAS-102 and regorafenib for patients with colorectal cancer ...

video

TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1

Howard S Hochster, MD of Yale Medical Center discusses TAS-102 and how it differ from more familiar agents, such as ...

video

RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib

Howard S Hochster, MD of Yale Medical Center discusses RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib at ASCO ...

video

Does the Asian population differ from the western populations in regards to gastric cancers

Manish Shah, MD of Weill-Cornell Medical Center, NYC answers the question does the Asian population differ from the western populations ...

video

The future of gastric cancers will be targeted agents including immunotherapy

Manish Shah, MD of Weill-Cornell Medical Center states that the future of gastric cancers will be targeted agents including immunotherapy ...

video

FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma

Joel Randolph Hecht, MD of UCLA Health discusses ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy ...

video

Phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma

Joel Randolph Hecht, MD of UCLA Health discusses phase II-III trial results T-DM1 in previously treated gastric and GE junction ...

video

Jeffrey A. Meyerhardt, MD, discusses how consensus molecular subtypes help with CRC treatment

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses how the four consensus molecular subtypes help with CRC ...

Related Videos

video-image

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

video-image

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

video-image

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

video-image

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

video-image

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

video-image

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

video-image

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

video-image

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

video-image

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

video-image

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

video-image

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

video-image

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

video-image

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

video-image

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

video-image

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

video-image

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

video-image

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

video-image

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

video-image

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

video-image

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

video-image

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

video-image

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

video-image

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

video-image

Johanna Bendell, MD, discusses the RESORCE trial data

video-image

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

video-image

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

video-image

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

video-image

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

video-image

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

video-image

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

video-image

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

video-image

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

video-image

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research